ammosamide A: structure in first source
ID Source | ID |
---|---|
PubMed CID | 25172829 |
CHEMBL ID | 4100877 |
SCHEMBL ID | 261071 |
MeSH ID | M0528859 |
Synonym |
---|
SCHEMBL261071 |
ammosamide a |
CHEMBL4100877 |
9,11-diamino-10-chloro-2-methyl-3-sulfanylidene-2,7-diazatricyclo[6.3.1.04,12]dodeca-1(11),4,6,8(12),9-pentaene-6-carboxamide |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1437640 | Cytotoxicity against human HCT116 cells assessed as growth inhibition by MTS assay | 2017 | Journal of natural products, 01-27, Volume: 80, Issue:1 | Thiol-Based Probe for Electrophilic Natural Products Reveals That Most of the Ammosamides Are Artifacts. |
AID1437645 | Antibacterial activity against Escherichia coli MG1655 at 10 ug after 48 hrs by disk diffusion method | 2017 | Journal of natural products, 01-27, Volume: 80, Issue:1 | Thiol-Based Probe for Electrophilic Natural Products Reveals That Most of the Ammosamides Are Artifacts. |
AID1437641 | Cytotoxicity against human HCT116 cells assessed as growth inhibition at 78.125 ug/ml by MTS assay relative to control | 2017 | Journal of natural products, 01-27, Volume: 80, Issue:1 | Thiol-Based Probe for Electrophilic Natural Products Reveals That Most of the Ammosamides Are Artifacts. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.36) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |